Skip to content

Alternative Delivery of Dose Adjustment For Normal Eating (DAFNE) Trial in Patients With Type 1 Diabetes

Improving Management of Type 1 Diabetes in the UK: The DAFNE Programme as a Research Test-bed - 5 x 1 Day RCT

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01069393
Enrollment
170
Registered
2010-02-17
Start date
2010-06-30
Completion date
2012-06-30
Last updated
2014-11-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 1 Diabetes Mellitus

Brief summary

The best format for the delivery of structured education for adults with Type 1 diabetes is unclear. Currently some hospitals invite their patients to attend a 5 day outpatient course run over one week (Dose Adjustment For Normal Eating (DAFNE)). Other centres offer 1 day a week for 3 to 5 weeks. We aim to find out whether or not the benefit of benefits are the same then it would mean that the course could routinely be offered to patients in either format, thus allowing more patient choice and flexibility.

Detailed description

The DAFNE (Dose Adjustment for Normal Eating) course is a 1-week structured education course teaching skills in insulin use and dietary freedom to individuals with Type 1 diabetes. At the moment, we do not understand enough about why some people get more out of the DAFNE programmes than others. Currently DAFNE is always taught over 1 week. We aim to find out whether or not the benefit of DAFNE is the same whether it is delivered over 5 consecutive days, or one day a week for 5 consecutive weeks. If the benefits are the same then it would mean that the course could routinely be offered to patients in either format, thus allowing more patient choice and flexibility. At present there have been no RCTs to address Approximately 170 people will take part in this study over the next 2 years. Half the people who participate will be allocated to attend a DAFNE course over 5 consecutive days, and the other halfwill attend one day a week for 5 consecutive weeks. We will perform routine biomedical assessments as part of the DAFNE programme and normal diabetes care (e.g. HbA1c (a measure of long-term blood glucose control), weight, blood pressure, blood biochemistry), and ask patients to recall hypoglycaemic (low blood sugar) events. We will also ask participants to fill in some research questionnaires, they will take 45-60 minutes to fill in each time. They will include questions about their diabetes, quality of life, well-being and diabetes knowledge. These assessments will be made at 3 time points; baseline, 6 and 12 months. The main outcome measure is change in HbA1c, with the other biomedical and psychosocial parameters being of secondary importance. These evaluations will help us develop the DAFNE programme further and inform us how best to deliver the course in the future.

Interventions

OTHERDAFNE course (Timing of delivery of education)

Education delivered over one day a week for 5 consecutive weeks, as opposed to 5 consecutive days over 1 week.

Sponsors

University Hospitals, Leicester
CollaboratorOTHER
Cambridge University Hospitals NHS Foundation Trust
CollaboratorOTHER
University College London Hospitals
CollaboratorOTHER
Northumbria Healthcare NHS Foundation Trust
CollaboratorOTHER
NHS Greater Glasgow and Clyde
CollaboratorOTHER
Norfolk and Norwich University Hospitals NHS Foundation Trust
CollaboratorOTHER
East Lancashire Hospitals NHS Trust
CollaboratorOTHER
Sheffield Teaching Hospitals NHS Foundation Trust
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* adults with Type 1 diabetes for at least 6 months * HbA1c \<12% * willing to undertake intensive insulin therapy

Exclusion criteria

* severe diabetic complications (making group education difficult) * inability to communicate in English * strong preference for on attending a one week course or one day a week for 5 consecutive weeks * inability to give informed consent

Design outcomes

Primary

MeasureTime frame
Improvement in HbA1c (glycosylated haemoglobin)6 & 12 months

Secondary

MeasureTime frame
Number of severe hypoglycaemic episodes12 months
Psychosocial measures, such as quality of life, emotional well-being, self-efficacy,will be assessed via questionnaires12 months
Qualitative evaluation via in-depth interviews to assess patients' experiences of the intervention12 months

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 25, 2026